16838-85-0 Usage
Uses
Used in Pharmaceutical Industry:
(3aS)-3a,4,5,6,6aβ,7,8,9,9aβ,9bα-Decahydro-8α-acetoxy-3,6,9-tris(methylene)azuleno[4,5-b]furan-2(3H)-one is used as a trypanocidal agent for its ability to combat trypanosomiasis, a disease caused by the parasitic protozoan Trypanosoma.
Used in Research and Development:
(3aS)-3a,4,5,6,6aβ,7,8,9,9aβ,9bα-Decahydro-8α-acetoxy-3,6,9-tris(methylene)azuleno[4,5-b]furan-2(3H)-one is also used in research and development for its potential applications in the discovery of new drugs and therapies, particularly in the field of infectious diseases and parasitology. Its trypanocidal activity makes it a valuable candidate for further study and development of novel treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 16838-85-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,8,3 and 8 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 16838-85:
(7*1)+(6*6)+(5*8)+(4*3)+(3*8)+(2*8)+(1*5)=140
140 % 10 = 0
So 16838-85-0 is a valid CAS Registry Number.
16838-85-0Relevant academic research and scientific papers
Studies on the Syntheses of Sesquiterpene Lactones. 11. The Syntheses of 3-Epizaluzanin C, Zaluzanin C, Zaluzanin D, and Related Compounds 3&α-Hydroxyguaia-1(10),4(15),11(13)-trieno-12,6&α-lactone and 3&α-Hydroxyguaia-4(15),9,11(13)-trieno-12,6&α-lactone
Ando, Masayoshi,Kusaka, Haruhiko,Ohara, Hiroshi,Takase, Kahei,Yamaoka, Hiroaki,Yanagi, Yoshikazu
, p. 1952 - 1960 (2007/10/02)
3-Epizaluzanin C (10), 3α-hydroxyguaia-1(10),4(15),11(13)-trieno-12,6α-lactone (36), and 3α-hydroxyguaia-4(15),9,11(13)-trieno-12,6α-lactone (37) have been synthesized in 4.0percent, 3.0percent, and 1.7percent overall yields, respectively, from α-santonine (13) in 14 steps.Zaluzanin C (11) and zaluzanin D (12) have also been synthesized in 2.4percent and 2.5percent overall yields from α-santonin (13) in 16 steps and 15 steps, respectively.The key step involves the solvolytic rearrangement of (11S)-3α,4α-epoxy-1β-(mesyloxy)eudesmano-13,6α-lactone (27).The stereochemistry of3-epizaluzanin C (10), zaluzanin C (11), and zaluzanin D (12) have been established by these stereospecific syntheses.
